Komori
Changes in Officers4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Subsidiary: Notice Regarding Personnel Changes at あすか製薬株式会社

At the CMC Quality Research Department of あすか製薬, Yamamura Yū (山村 雄), manager of Analysis Section 2, was promoted to department head and will concurrently serve as manager of Analysis Section 2.

Worth reading
16Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 2025年9月24日

Incoming appointee

1 item
Scheduled Appointment Date1 October 2025
山村 雄
Previous position生産本部 CMC品質研究部 分析2課長
New position生産本部 CMC品質研究部長 兼 分析2課長
Who is moving to which position
ItemDetails
Resolution date2025年9月24日
Scheduled Appointment Date1 October 2025
Name of appointee山村 雄
Appointee's new position生産本部 CMC品質研究部長 兼 分析2課長
Appointee's previous position生産本部 CMC品質研究部 分析2課長
Items this document does not state (16)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reason for the personnel change is not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Subsidiary: Notice Regarding Personnel Changes at あすか製薬株式会社 | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori